Histology Classification Highlights Differences in Efficacy of S-1 versus Capecitabine, in Combination with Cisplatin, for HER2-Negative Unresectable Advanced or Recurrent Gastric Cancer with Measurable Disease

Neoadjuvant docetaxel, oxaliplatin and S‑1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902) protocol of a multi‑center, phase II study

The Phase II Study of Panitumumab in Chemotherapy- Naïve Frail or Elderly Patients with RAS Wild-type Colorectal Cancer OGSG 1602 Final Results

Protocol of OGSG 1901 a phase II trial of ramucirumab plus irinotecan for patients with early relapsed gastric cancer during or after adjuvant docetaxel plus S − 1 therapy

Sequential Treatment Strategy Using Fluoropyrimidine plus Bevacizumab Followed by Oxaliplatin for Metastatic Colorectal Cancer A Phase II Study (OGSG 1107)

Three-year outcomes of a phase Ⅱ study of adjuvant chemotherapy with S-1 plus docetaxel for stage Ⅲ gastric cancer after curative D2 gastrectomy

Randomized, Open-Label Phase II Study Comparing Capecitabine- Cisplatin Every 3 Weeks with S-1-Cisplatin Every 5 Weeks in Chemotherapy-Naïve Patients with HER2-Negative Advanced Gastric Cancer: OGSG1105, HERBIS-4A Trial

Trastuzumab With S-1 Plus Cisplatin in HER2-positive Advanced Gastric Cancer Without Measurable Lesions: OGSG 1202

高度リンパ節転移を伴う進行胃癌に対する術前カペシタビン＋ シスプラチン療法第Ⅱ相臨床試験（OGSG1401)

Phase II study of 5‑fluorouracil–leucovorin plus bevacizumab for chemotherapy‑naïve older or frail patients with metastatic colorectal cancer (OGSG 0802)